What’s New at PCL
The PCL is offering a new service. The Seahorse Bioscience XF24 is a fully-integrated instrument that simultaneously measures the two major energy yielding pathways – aerobic respiration and glycolysis – in a convenient, 24 well microplate format. The system is ideal for measuring metabolic changes in cells in response to ligand stimulation or drug treatment. PCL will train new users who will then have walk up access to the instrument. In addition PCL staff can also perform experiments for investigators by submitting requests to the CSAS system. For more information please contact Dr. Andrew Stephen (301-846-1634).
Mesothelin, a cell surface tumor associated antigen, is expressed in several human cancers. It is shed from the surface negatively impacting it’s use as a immunotherapeutic target. PCL Senior Scientist, Oleg Chertov identified the cleavage site of shed mesothelin in a collaboration with Dr. Ira Pastan (Laboratory of Molecular Biology, NCI). For more information, click here. To link to the full paper, click here.
The PCL collaborates closely with NCI investigators as well as engages in technology development. The publications below highlight these activities.
Lee HS, Park JW, Chertov O, Colantonio S, Simpton JT, Fivash MJ, Yoo CW, Lee GK, Zo JI, Kim HT, Kim HK: Matrix-assisted laser desorption/ionization mass spectrometry reveals decreased calcyclin expression in small cell lung cancer. Pathol. Int, 62(1):28-35, 2012
Zhang Y, Chertov O, Zhang J, Hassan R, Pastan I: Cytotoxic Activity of Immunotoxin SS1P Is Modulated by TACE-Dependent Mesothelin Shedding. Cancer Res, 71(17):5915-22, 2011
Colantonio S, Simpson JT, Fisher RJ, Yavlovich A, Belanger JM, Puri A, Blumenthal R: Quantitative analysis of phospholipids using nanostructured laser desorption ionization targets. Lipids, 46(5):469-477, 2011
Ho M, Feng M, Fisher, RJ, Rader C, Pastan I: A novel high-affinity human monoclonal antibody to mesothelin. Int. J. Cancer, 128(9):2020-2030, 2011
Kim SE, Liu F, Im YJ, Stephen AG, Fivash MJ, Waheed AA, Freed EO, Fisher RJ, Hurley JH, Burke TR Jr: Elucidation of New Binding Interactions with the Tumor Susceptibility Gene 101 (Tsg101) Protein Using Modified HIV-1 Gag-p6 Derived Peptide Ligands. ACS Med Chem Lett, 2(5):337-341
Ramalinga U, Clogston JD, Patri,AK, Simpson JT: Characterization of nanoparticles by matrix assisted laser desorption ionization time-of-flight mass spectrometry. Methods Mol Biol 697:53-61
Chertov O, Zhang Z, Chen X, Oppenheim JJ, Lubkowski J, McGrath C, Sowder, RC, Crise BJ, Malyguine A, Kutzler MA, Steele AD, Henderson EE, Rogers TJ: Novel Peptides Based on HIV-1 gp120 Sequence with Homology to Chemokines Inhibit HIV Infection in Cell Culture. PLoS ONE 6(1): e14474, 2011.
Dexheimer TS, Stephen AG, Fivash MJ, Fisher RJ, Pommier Y: The DNA binding and 3′-end preferential activity of human tyrosyl-DNA phosphodiesterase. Nucleic Acids Res, 38(7):2444-2452, 2010.
Ho M, Feng M, Fisher RJ, Rader C, Pastan I: A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer, Jul 15. [Epub ahead of print], 2010.
Kim HK, Reyzer ML, Choi IJ, Kim CG, Kim HS, Oshima A, Chertov O, Colantonio S, Fisher RJ, Allen JL, Caprioli RM, Green JE: Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. J Proteome Res, 9(8):4123-4130, 2010.
Liu F, Stephen AG, Waheed AA, Freed EO, Fisher RJ, Burke TR Jr: Application of ring-closing metathesis macrocyclization to the development of Tsg101-binding antagonists. Bioorg Med Chem Lett, 20(1):318-321, 2010.